NLS-133 Non-Hormonal Oral Contraceptive
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Pericoital
- Development Stage: Phase II
- Developer(s)/researcher(s): NEXT Life Sciences
Details
- API: Not Public - Combination of Two APIs
-
Mechanism of Action:
- Other
- Regimen: On Demand
- MPT: Not Potential MPT
- Promising Attributes: Developers indicate that NLS-133 would allow for male-controlled, on-demand contraception with anticipated rapid time to efficacy
Product Status
Active/Recent Clinical Research
History
2026: NEXT Life Science announces the initiation of Ph II clinical research for their candidate product NLS-133, an oral contraceptive intended for on-demand use by male users. Ph II trial concluded in May 2026. The contraceptive is intended to significantly reduce semen volume and sperm count in semen for up to 24 hours. While NLS-133's API is not yet public, the clinical trial record indicates that the product contains two US FDA-approved drugs.